Laparoscopic surgery in a woman with factor V deficiency: revisiting platelet factor V

Surgical management of the patient with factor V deficiency: a case report

“…The patient was followed up with 2 units FFP replacement 2 times in a day for 72 hours after the operation. 4 FV deficiency can lead to life-threatening bleeding. 10 In our patient, the bleeding did not stop from the hemorrhagic cyst and torsioned has occurred in the left ovary.…”

Recombinant FVIIa therapy for heavy menstrual bleeding in patients with severe FV deficiency

“…Advances in the management and treatment of haemophilia include the development of new therapeutic products, interventions and monitoring techniques. [1][2][3][4][5][6] The introduction of these and other developments into clinical practice will necessarily generate complexities, in addition to existing unmet needs requiring attention by physicians who treat patients with haemophilia. To gain an understanding of these needs, it is necessary to implement a process that surveys a wide range of expert frontline clinicians who have knowledge of current drivers in haemophilia care.…”

“…The literature contains only a few reports of heavy menstrual bleeding in patients with severe FV deficiency. [3][4][5][6]9 Treatment regimens with FFP, antifibrinolytics, desmopressin and oral contraceptives…”

“…have not yet been optimized, and it can be difficult to control heavy menstrual bleeding episodes with these methods. [3][4][5][6] Administration of additional hormonal manipulation may be useful in managing bleeding but has not been proven to be optimal treatment for heavy menstrual bleeding. 10 Bypassing-agent monotherapy has been used with variable success in most patients with severe FV deficiency who have inhibitors or are allergic to FFP.…”

“…Because platelets provide 18%-25% of the total FV in plasma, use of platelet transfusion has been recommended in cases where FFP cannot control severe bleeding. 5 However, in patients with these bleeding episodes, rVIIa therapy seems more appropriate considering the risks of infection and volume overload associated with FFP and platelet transfusions. The dosages of rVIIa used in cases of FV deficiency in the literature and in our case were based on the recommended dosage for haemophilia patients with inhibitors (ie, bolus injection of approximately 90 μg/kg).…”